VitroLabs is a startup working on the cutting edge of 3D tissue engineering using stem cell-based technologies. The company develops a fully scalable tissue engineering platform combining the latest breakthroughs in stem cell research and biomaterials. It manufactures real leather without the need to raise and slaughter animals using breakthroughs in stem cell research and tissue engineering. VitroLabs was founded on 2016 and is based in San Jose, California.
Leaft Foods exists to reduce the environmental impact of food production. We capture the most plentiful protein on the planet, Rubisco from green leaves.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Apton Biosystems develops an optical system designed for sequencing and protein detection, using super-resolution to assess molecules spaced closer than a wavelength of light. It enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.
Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient. The company is committed to transforming the way providers prescribe drugs, as well as the way manufacturers, develop new drugs. They are building a molecular map of all protein interactions that identifies genomic signatures and links those to disease and predictive treatment outcomes. Using a simple blood sample to analyze RNA, Scipher Medicine can predict if a patient is likely to respond to a targeted therapy before therapy is prescribed. This insight allows patients to start the most effective therapy from day one. For its first commercial product, they have developed PrismRA®, a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to TNFi therapies such as Humira® and Enbrel® so that such patients can go on alternative approved drugs. Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don't respond to treatment, costing the healthcare industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A routine blood test predicts which drug he/she will respond to, with our first product focusing on rheumatoid arthritis, ensuring that the most optimal treatment is prescribed from day one. The molecular data generated by our tests are then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Ontera develops a hand-held point of use diagnostic platform that examines DNA and RNA, and analytes (proteins, viruses, antibodies, etc) from any life form. Use in human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more. Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Clear Labs offers next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. The company's platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens and support public health initiatives. The company focuses on delivering actionable insights to enhance safety and operational efficiency in various sectors.
Apton Biosystems develops an optical system designed for sequencing and protein detection, using super-resolution to assess molecules spaced closer than a wavelength of light. It enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators.